Comparing Body Composition Changes: GLP-1 Agonists vs. Gastric Bypass Surgery

The global prevalence of obesity continues to rise, leading to significant health complications like type 2 diabetes, cardiovascular disease, and certain cancers. While GLP-1 receptor agonists (GLP-1 RAs) and gastric bypass surgery are highly effective weight loss interventions, there's a critical need to understand their comparative impacts on specific body composition changes, beyond just overall weight loss. This REFORM Study (NCT07115069) directly addresses this by comparing the precise changes in body fat and lean muscle mass induced by these two distinct approaches.

As this study is currently recruiting and has not yet commenced data collection, there are no findings to report at this time. However, the REFORM Study is designed to rigorously investigate and quantify the differential effects of these powerful interventions. Researchers will specifically analyze how GLP-1 receptor agonists compare to both laparoscopic and robotic gastric bypass surgery in altering body composition. The primary objective is to provide detailed insights into these changes. The study's central goal is to precisely measure and compare the specific changes in body composition, including fat mass and lean mass, induced by GLP-1 receptor agonists versus laparoscopic and robotic gastric bypass surgery in patients with obesity.